Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$76.80
-0.20 (-0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-933.8M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-95.0%
↓Gross Margin
68.2%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.7%
FCF CAGR
—
FCF margin
-198.9%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $431.3M · net income $-883.2M · FCF $-857.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $431.3M | $431.3M | $418.7M | $195.0M | $301.5M |
| Net Income | $-883.2M | $-883.2M | $-1.08B | $-1.04B | $-472.6M |
| EBITDA | $-784.5M | $-784.5M | $-946.0M | $-912.2M | $-386.6M |
| EPS | — | — | -7.87 | -8.14 | -4.00 |
| Gross Margin | 68.2% | 68.2% | 57.3% | 58.4% | 91.5% |
| Operating Margin | -199.9% | -199.9% | -257.9% | -516.6% | -155.7% |
| Net Margin | -204.8% | -204.8% | -258.2% | -531.3% | -156.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.16 | 0.18 | 0.05 |
| Current Ratio | 13.61 | 13.61 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-857.7M | $-857.7M | $-1.33B | $-933.8M | $-291.3M |
| Returns | |||||
| ROE | -95.0% | -95.0% | -67.6% | -83.3% | -51.9% |
| Valuation | |||||
| P/B | 13.01 | 13.01 | 6.63 | 9.69 | 11.80 |
| Growth & Yield | |||||
| Revenue Growth | 3.0% | 3.0% | 114.7% | -35.3% | — |
| EPS Growth | — | — | 3.3% | -103.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.87 → n/d
Residual
+19.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.